Retaane
(anecortave acetate)PreclinicalSmall molecule
Anecortave acetate is used to treat wet age-related macular degeneration, a condition that causes vision loss in older adults by damaging the central part of the retina at the back of the eye.[1] Retaane is currently being investigated across 3 indications[3], with its most advanced program in Preclinical.[1]
Retaane is one of 20 small molecule programs targeting Ocular Vascular Disease. It is currently in Preclinical.
3
Indications
30
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Macular Degeneration
#DrugCompanyPhaseTrials
1Vabysmo
RocheApproved
Copaxone
TevaApproved
Iheezo
BB. Braun Medical Inc.
Approved
Avastin
RochePhase 3
Caverject
VViatris Specialty LLC
Approved
Visudyne
BBausch Health Americas, Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
OTX-TKI
OOcular Therapeutix, Inc.
Phase 3
Tiespectus
EEyeBiotech Ltd.
Phase 3
Faricimab Injection [vabysmo]
CCincinnati Eye Institute, Southwest Ohio
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Treatment6 trials
Age-Related Macular Degeneration5 trials
Open-Angle Glaucoma3 trials
Trial3 trials
9 more indications
Ocular Hypertension2 trials
Intraocular Pressure2 trials
Retinal Vein Occlusion1 trial
Wet Age-Related Macular Degeneration1 trial
CLE1 trial
Diabetic Retinopathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anecortave acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAlcon Research